 |
AURUM
Biosciences Ltd is a biopharmaceutical company
developing novel oxygen carriers and proprietary software for use with
MRI, initially for Acute Ischaemic Stroke (AIS). Follow-on indications
include heart disease, cancer, epilepsy, and dementia. Together with
its US partner, Oxygen Biotherapeutics , Inc. www.oxybiomed.com, the
company is taking a stroke management product ("GOLD") through
preclinical development and into clinical studies of efficacy and
safety. Read more  |
| Diagnosis
and Treatment of Stroke |
GOLD Technology | The
Management Team |
 |
 |
 |
| Diagnosis
and Treatment of Stroke:
Current diagnostic approaches do not provide reliable or complete data
on the severity of brain damage and the potential for injured tissue to
recover. When the patient arrives at the hospital it is expected that a
GOLD "penumbra" scan will quickly and accurately identify the amount of
potentially salvageable tissue. There Read more |
GOLD
combines OBI's oxygenated
perfluorocarbon (PFC) Oxycyte with proprietary software to provide
improved magnetic resonance imaging (MRI) of damaged brain tissue.
Since the delivery of oxygen to hypoxic tissue will ameliorate survival
of injured tissue, it has the potential for both diagnostic and
therapeutic applications. Read more |
The
Management Team is composed of
industry experts in the development and commercialization of
biopharmaceuticals and experienced scientists, including the medical
and scientific founders. Read more |
- Stroke: 2nd most common cause of death and major disability worldwide; 2 million patients in EU
- £2Bn Stroke market, only 5% of patients are treated, only 1 stroke therapy and no accurate diagnostic.
- The acute ischaemic stroke landscape shows few promising competitors in the pipeline. GOLD is based on a patented technology from one of Europe's leading stroke centres. It is expected to be extremely safe.
